Michael Robert Horsman

Professor

CURRICULUM VITAE

MICHAEL ROBERT HORSMAN
BornDecember 3, 1953, London, England
NationalityBritish
Home addressJernaldervej 300, 8210 Aarhus V, Denmark

Education

1959-1965Michael Faraday Primary and Junior School, London, England
1965-1973Archbishop Tenison's Grammar School, London England
1974-1977Oxford Polytechnic, Oxford, England
1977-1980University of London, Sutton, Surrey, England

Academic degrees

1977B.Sc. (Hons) in human biology
1981PhD in radiation biology
1996D.M.Sc. in Medical Science

Present position

Professor of Experimental Radiotherapy, Department of Experimental Clinical Oncology, Aarhus University Hospital, Nørrebrogade 44, DK-8000 Aarhus C, Denmark, (2012-present)

Previous research appointments

1977-1980PhD Student, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, England.
1981-1986Research Associate, Department of Therapeutic Radiology, Division of Radiobiology Research, Stanford University, Stanford, California, USA
1987-1989Research Scientist, Danish Cancer Society, Department of Experimental Clinical Oncology, Aarhus, Denmark
1990-1997Senior Scientist, Danish Cancer Society, Department of Experimental Clinical Oncology, Aarhus, Denmark
1997-2012Associate Professor, Aarhus University, Denmark

Awards and grants

The 11th Annual Robert F. Kallman Memorial Lecture (2014)
The Order of St. John Fellowship Anniversary Silver Medal Award (2013)
The B.B. Singh Oratory (2012)
Winner of the ESHO-BSD Award (2011)
The Martin Lindgren Lecture (1998)
Winner of the 1988 Lund Science Award
Conference on Chemical Modifiers of Cancer Treatment, Junior Investigator Award, Clearwater, FL, USA, October (1985)
CROS Conference on Chemical Modifiers of Cancer Treatment, Junior Investigator Award, Banff, Alberta, Canada, December (1983)
Seventh International Congress on Radiation Research, Junior Investigator Award, Amsterdam, The Netherlands, July (1983)
CROS Conference on Chemical Modification : Radiation and Cytotoxic Drugs, Junior Investigator Award, Key Biscayne, FL, USA, September (1981)
Radiation Research Society Student Travel Award, New Orleans, LA, USA, May (1980)

Publications and presentations

Number of publications: 253, Peer-revied articles: 163, Book chapters: 37,
H-index: 44, Number of citations: 5615, Scientific meeting presentations (oral): 155.

Board memberships

Secretary General and Scientific Secretary of the European Society for Hyperthermic
Oncology (2013-)
Member of the board of the European Society for Hyperthermic Oncology (2003-2006, 2008-2011, 2013-)
Member of the board of the Danish Association for Cancer Research (2005-2008)
Secretary/Treasurer of the International Association for Hyperthermic Oncology (2004-2008)

Supervision

Supervisor for 12 PhD students at Faculty of Health Sciences, Aarhus University, Denmark
Supervisor for 1 PhD student at the Medical Faculty, University of Turku
Supervisor for 3 Diploma students at Faculty of Health Sciences, Aarhus University, Denmark
Supervisor for 1 MSc student at the School of Pharmacology, University of Bath, England

Evaluations

MIDWAY QUALIFYING EXAM FOR PHD.:
2 students at Science and Technology, Aarhus University, Denmark

PHD. THESIS:
1 student at Health, Aarhus University, Denmark
1 student at University of Lund, Sweden
2 students at University of London, UK
1 student at University of Padova, Italy
1 student at University of British Columbia, Canada
1 student at University of Copenhagen, Denmark
1 student at University of Oslo, Norway

M.Sc. THESIS:
1 student at University of Aukland, New Zealand
1 student at Health, Aarhus University, Denmark
1 student at University of Southern Denmark, Denmark

Dr. PHILOS THESIS:
6 students at University of Oslo, Norway

D.M.Sc. THESIS:
1 student at University of Copehagen, Denmark
2 students at University of Bergen, Norway

M.D. THESIS:
1 student at University of London, UK

Major research grants

Danish Cancer Society: Identifying and targeting the different microenvironmental and vascular features of tumours to improve radiotherapy outcome (2012-2014)
Therapeutic impact of the tumour microenvironment and vasculature (2008-2010)

The Danish Council for Independent Research | Medical Sciences: Bioimaging of tumour hypoxia to improve the therapeutic outcome in cancer patients (2006-2008)

The Danish Council for Independent Research | Medical Sciences: Improving cancer therapy by targeting the tumour vasculature: Optimizing and exploiting novel and established approaches (2010-2012)

External grant reviewer

Association for International Cancer Research
AstraZeneca Research and Educational Scholarships
Belgian Foundation Against Cancer
Dutch Cancer Society
Flanders Research Foundation
Flight Attendant Medical Research Institute
Health Research Council of New Zealand
Medical Research Council of Canada
NATO Collaborative Research Grants
Shota Rustaveli National Science Foundation of Georgia
U.K. Cancer Research Campaign
University of Antwerp Research Council

Organisation of scientific conferences

Member of the Organising Committee of the Tumour Hypoxia Meeting, April 9-11, 1986, Vancouver, British Columbia, Canada.
Member of the Organising Committee for the COMAC-BME Workshop on Clinical Evaluation of Hyperthermia, February 23-25, 1990, Copenhagen, Denmark.
Member of the Organising Committee of the 3rd International Workshop on Tumor Hypoxia, July 2-5, 1991, Orillia, Ontario, Canada.Organiser of the Workshop on The Potential of NMR Spectroscopy for In Vivo Cancer Research, April 26-27, 1993, Aarhus, Denmark.
Member of the Scientific Committee of the 13th Annual Conference of the European Society for Hyperthermic Oncology, June 16-19, 1993, Brussels, Belgium.
Chairman of the Organising Committee of the International Workshop on Tumour Microenvironment: Its Characterization, Modification and Clinical Implications, September 23-25, 1994, Granada, Spain.
Member of the Scientific Programme Committee of the 3rd Inter¬national ARCON Workshop, August 14-17, 1996, Umeå, Sweden.
Member of the Organizing Committee of the International Workshop on the Tumor Microenvironment: An Important Paradigm in Cancer Etiology and Treatment, April 28 - May 2, 1997, Martha's Vineyard, RI, USA.
Member of the Programme Committee of the 10th International Conference on Chemical Modifiers of Cancer Treatment, January 28-31, 1998, Clearwater, FL, USA.
Co-organizer of the Workshop on Non-invasive Imaging of Tumour Hypoxia, November 21, 1998, Aarhus, Denmark.
Organizer of the Danish Society for Cancer Research Meeting on "Damaging established tumour vasculature: an alternative to anti-angiogenesis approaches", August 25, 1999, Copenhagen, Denmark.
Member of the Scientific Committee of the 18th Annual Meeting of the European Society for Hyperthermic Oncology, September 1-4, 1999, Rotterdam, The Netherlands.
Member of the Organizing Commitee of the NOS-M Symposium on Angiogenesis, January 7-9, 2000, Gentofte Denmark. 
Member of the Scientific Committee of the 8th International Congress of Hyperthermic Oncology, April 26-29, 2000, Kyong-Ju, Korea.
Member of the Programme Committee of the 19th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September 17-21, 2000, Istanbul, Turkey.
Member of the Faculty of the 11th International Conference on Chemical Modifiers of Cancer Treatment, October 5-7, 2000, Banff, Alberta, Canada.
Member of the Organizing Committee of the 7th International Workshop on the Tumor Microenvironment and Its Impact on Cancer Therapies, April 19-21, 2001, Atlanta, GA, USA.
Member of the Scientific Committee of the 19th Annual Meeting of the European Society for Hyperthermic Oncology, May 30 - June 2, 2001, Verona, Italy.
Organizer and Chairman of the Scientific Programme Committee of the 1st ESTRO Workshop on Biology in Radiation Oncology, June 10-12, 2001, Fuglsø, Denmark.
Member of the Organizing Committee of the 8th International Workshop on the Tumor Microenvironment and Its Impact on Cancer Therapies, May 3-7, 2003, Miami, FL, USA.
Member of the Scientific Committee of the 2nd ESTRO Workshop on Biology in Radiation Oncology, June 1-3, 2003, Nijmegen, The Netherlands.
Member of the Scientific Programme Committee of the 9th International Congress on Hyperthermic Oncology, April 20-24, 2004, St. Louis, MO, USA.
Member of the Scientific Radiobiology Committee of the 23rd Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September, 2004, Amsterdam, The Netherlands.
Member of the programme Committee for the 18th Annual Meeting of the Danish Society for Cancer Research, May 4, 2005, Vilvorde, Denmark.
Member of the Scientific Committee of the 22nd Annual Meeting of the European Society for Hyperthermic Oncology, June 8-11, 2005, Graz, Austria.
Member of the Organizing Committee of the 9th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, August 20-23, 2005, Oxford, UK.
Member of the programme Committee for the 19th Annual Meeting of the Danish Society for Cancer Research, May 5, 2006, Vilvorde, Denmark.
Member of the Organizing Committee of the 10th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, September 15-18, 2006, Boston, USA.
Member of the Programme Committee for the 20th Annual Meeting of the Danish Society for Cancer Research, May 11, 2007, Vilvorde, Denmark.
Co-Organiser of the 3rd European Society for Hyperthermic Oncology Educational Day, June 13, 2007, Prague, Czech Republic.
Member of the Programme Committee for the 21st Annual Meeting of the Danish Society for Cancer Research, April 30, 2008, Vilvorde, Denmark.
Member of the Organizing Committee of the 11th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, May 15-17, 2008, Miami, USA.
Member of the Scientific Committee of the International Conference on Tumor hypoxia and malignant progression, October 1-4, 2008, Kiev, Ukraine.
Member of the Organizing Committee of the 12th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, May 2-5, 2010, Toronto, Canada
Member of the International Scientific Programme Committee of the International Conference on Tumor and Host: novel aspects of old problem, September 21-24, 2010, Kiev, Ukraine.
Organiser of the 7th European Society for Hyperthermic Oncology Educational Day, May 25, 2011, Aarhus, Denmark.
Organiser of the 27th Annual Meeting of the European Society for Hyperthermic Oncology, May 26-28, 2011, Aarhus, Denmark.
Member of the Scientific Committee of the 12th International Wolfsberg Meeting on Molecular Radiation Biology/Oncology, June 25-27, 2011, Ermatingen, Switzerland.
Member of the Organizing Committee of the Aarhus PET-MR Hybrid Scanner Workshop on Instrumentation, Development, Research and Clinical Application, June 29, 2011, Aarhus, Denmark.
Member of the Organizing Committee of the 13th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, May 2-4, 2013, Miami, USA.
Member of the Local Organizing Faculty of the 11th Acta Oncologica Symposium BiGART 2013, June 11-13, 2013, Aarhus, Denmark.
Member of the Scientific Committee of the 28th Annual Meeting of the European Society for Hyperthermic Oncology, June 19-22, 2013, Munich, Germany.
Member of Board of Directors of the European Society for Hyperthermic Oncology School on Hyperthermia & Thermal Ablation in Cancer Therapy, February 3-6, 2014, Huntsham, UK.
Member of the Scientific Committee of the 29th Annual Meeting of the European Society for Hyperthermic Oncology, June 11-14, 2014, Torino, Italy.
Member of the Local Organizing Faculty of the 12th Acta Oncologica Symposium BiGART 2015, June 10-12, 2015, Aarhus, Denmark.
Member of the Scientific Committee of the 30th Annual Meeting of the European Society for Hyperthermic Oncology, June 24-27, 2015, Zurich, Switerland.
Member of the Organizing Committee of the 14th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, August 27-29, 2015, Vancouver, Canada.
Member of the Organizing Committee of the 15th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, April 27-29, 2017, Miami, USA.
Member of the Local Organizing Faculty of the 13th Acta Oncologica Symposium BiGART 2017, June 13-16, 2017, Aarhus, Denmark.
Member of the Scientific Committee of the 31st Annual Meeting of the European Society for Hyperthermic Oncology, June 21-23, 2017, Athens, Greece.

Session chairmanship

Chairman of the Session on Hypoxic Cell Sensitizers I, at the 34th Annual Radiation Research Society Meeting, April 12-17, 1986, Las Vegas, NV, USA.
Chairman of the Session on Immunology and Physiological Effects, at the 37th Annual Radiation Research Society ¬Meeting, March 19-23, 1989, Seattle, WA, USA.
Organizer and Chairman of the Workshop on Vascular and En¬viron¬mental Effects of Hyperthermia, at the 10th Annual Euro¬pean Society for Hyperthermic Oncology Meeting, September 21-23, 1989, Amsterdam, The Netherlands.
Chairman of the Session on Tumor Hypoxia - Impact on Radiation Response, at the 3rd International Workshop on Tumor Hypoxia, July 2-5, 1991, Orillia, Ontario, Canada.
Session chairman at the Workshop on Bioreductive Drugs, Sensitizers, Oxygen, and Radiation, October 20-22, 1991, Vienna, Austria.
Organizer and Chairman of the Workshop on Tumour Physiology and the Response to Heat: Clinically Relevant Predictive Assays and Methods of Modification, at the 6th International Congress of Hyperthermic Oncology, April 26 - May 1, 1992, Tucson, AZ, USA.
Session Chairman at the Workshop on The Potential of NMR Spectroscopy for In Vivo Cancer Research, April 26-27, 1993, Aarhus, Denmark.
Chairman of the Session on Manipulation of Tumor Oxygen and Physiology, at the 8th International Conference on Chemical Modifiers of Cancer Treatment, June 16-19, 1993, Kyoto, Japan.
Chairman of the Session on Preclinical Study, at the Interna¬tional Congress of Radiation Oncology - 1993, June 21-25, 1993, Kyoto, Japan.
Session Chairman at the Workshop on The Tumour Microenvironment: Its Characterization, Modification and Clinical Implications, September 23-25, 1994, Granada, Spain.
Session Chairman at the 9th International Conference on Chemical Modifiers of Cancer Treatment, August 22-26, 1995, Oxford, England.
Session Chairman at the 15th Annual Meeting of the European Society for Hyperthermic Oncology, September 3-6, 1995, Oxford, England.
Organizer and Chairman of the Symposium on Clinical and Physical Advances on the Study of Tumor Micro-Environment and Clinical Heat Response, at the 7th International Congress of Hyperthermic Oncology, April 9-13, 1996, Rome, Italy.
Chairman of the Session on Tumour Microenvironment at the 15th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September 23-26, 1996, Vienna, Austria.
Chairman of the Session on Cellular and Physiological Effects of Hyperthermia at the 16th Annual Meeting of the European Society for Hyperthermic Oncology, April 2-5, 1997, Berlin, Germany.
Session Chairman at the Workshop on the Tumour Microenvironment: An Important Paradigm in Cancer Etiology and Treatment, April 28 - May 2, 1997, Martha's Vineyard, RI, USA.
Chairman of the Session on Tumour Biology at the 17th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September 20-24, 1998, Edinburgh, UK.
Chairman of the Session on Oxidative Metabolism at the 8th Symposium on the Medical Applications of Cyclotrons, May 22-25, 1999, Turku, Finland.
Chairman of the Session on Enhancing Therapy at the International Workshop on the Tumour Microenvironment, July, 15-17, 1999, Belfast, UK.
Chairman of the Session on WBHT and Three-Modality at the 18th Annual Meeting of the European Society for Hyperthermic Oncology, September 1-4, 1999, Rotterdam, The Netherlands.
Session Chairman at the 41st Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, October 31 - November 4, 1999, San Antonio, TX, USA.
Chairman of the Session on Vasculature, Angiogenesis and Hypoxia at the First International Conference on Translational Research and Pre-Clinical Strategies in Radio-Oncology, March 5-8, 2000, Lugano, Switzerland.
Session Chairman at the 8th International Congress of Hyperther¬mic Oncology, April 26-29, 2000, Kyong-Ju, Korea.
Chairman of the Session on Tumor Oxygenation/Physiology at the 11th International Conference on Chemical Modifiers of Cancer Treatment, October 5-7, 2000, Banff, Alberta, Canada.
Chairman of the Session on Tumor Physiology and Treatment Outcome at the 42nd Annual Meeting of the American Society for Therapeu¬tic Radiology and Oncology, October 22-26, 2000, Boston, MA, USA.
Chairman of the Session on Anti-Vascular/Anti-Angiogenic Therapies at the 7th International Workshop on The Tumour Microenvironment and Its Impact on Cancer Therapies, April 19-21, 2001, Atlanta, GA, USA.
Chairman of the Session on Cellular and Physiological Mechanisms at the 19th Annual Meeting of the European Society for Hyperthermic Oncology, May 30-June 2, 2001, Verona, Italy.
Chairman of the Session on Modifying Microenvironment at the 21st Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September 17-21, 2002, Praha, Czech Republic.
Chairman of the Teaching Lecture on Translational Research in Radiation Oncology at the 12th Annual Meeting of the European Cancer Congress, September 21-25, 2003, Copenhagen, Denmark.
Session Chairman at the 9th Annual Scientific Meeting of the Sector for Clinical research, Dept. Oncology, Aarhus University Hospital, October 3-4, 2003, Fuglsøcentret, Mols, Denmark.
Chairman of the Session on Low Molecular Weight Vascular Targeting Agents at the 2nd International Conference on Vascular Targeting, May 16-18, 2004, Miami, FL, USA.
Chairman of the Session on Hypoxia and Angiogenesis at the 23rd Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September, 2004, Amsterdam, The Netherlands.
Chairman of the Biology Session at the 22nd Annual Meeting of the European Society for Hyperthermic Oncology, June, 2005, Graz, Austria.
Session Chairman at the 9th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, August 20-23, 2005, Oxford, UK.
Chairman of the Session on Cell-Microenvironment at the 3rd International Conference on Translational Research and pre-clinical Strategies in Radiation Oncology, March 12-15, 2006, Lugano, Switzerland.
Chairman of the Preclinical Research Session at the 23rd Annual Meeting of the European Society for Hyperthermic Oncology, May 24-27, 2006, Berlin, Germany.
Chairman of the Characterisation Session at the 10th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, September 15-17, 2006, Boston, USA.
Chairman of the Session on Vascular Targeting at the 24th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, October 8-12, 2006, Leipzig, Germany.
Chairman of the Session on Mechanisms and experimental therapy at the 20th Annual Meeting of the Danish Association for Cancer Research, May 11, 2007, Vilvorde, Denmark.
Chairman of the Session on Vascular mediated responses to heat at the 3rd European Society for Hyperthermic Oncology Educational Day, June 13, 2007, Prague, Czech Republic.
Chairman of the Session on Biological Developments at the 24th Annual Meeting of the European Society for Hyperthermic Oncology, June 14-16, 2007, Prague, Czech Republic.
Chairman of the Session on Physiological effects of Hyperthermia at the 10th International Congress on Hyperthermic Oncology, April 9-12, 2008, Munich, Germany.
Chairman of the Session on Pathological Considerations at the 11th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, May 15-17, 2008, Miami, USA.
Chairman of the Session on Hypoxia and Vasculature at the 25th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September 14-18, 2008, Göteborg, Sweden.
Session Chairman International Conference on Tumor hypoxia and malignant progression, October 1-4, 2008, Kiev, Ukraine.
Chairman of the Session on Biological Imaging at the 4th International Conference on Translational Research and pre-clinical Strategies in Radiation Oncology, March 11-13, 2009, Geneva, Switzerland.
Chairman of the Biological Session on Chemo-hyperthermia in disease progression at the 25th Annual Meeting of the European Society for Hyperthermic Oncology, June 4-6, 2009, Verona, Italy.
Chairman of the Session on Angiogenesis and Cancer Therapies at the 25th Annual Meeting of the European Society for Hyperthermic Oncology, June 4-6, 2009, Verona, Italy.
Chairman of the Session on Imaging and Therapy Predictions at the 12th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, May 2-5, 2010, Toronto, Canada.
Chairman of the Session on Pathophysiological Effects at the 26th Annual Meeting of the European Society for Hyperthermic Oncology, May 20-22, 2010, Rotterdam, The Netherlands.
Chairman of the Keynote Lecture on Thermotherapy with Magnetic Nanoparticles at the 27th Annual Meeting of the European Society for Hyperthermic Oncology, May 26-28, 2011, Aarhus, Denmark.
Chairman of the Session on Establishing Hyperthermia in Australia at the 27th Annual Meeting of the European Society for Hyperthermic Oncology, May 26-28, 2011, Aarhus, Denmark.
Chairman of the Session on Tumor Physiology, Therapy Response and Resistance at the 13th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, May 2-4, 2013, Miami, USA.
Chairman of the Session on Biological Imaging Developments at the 11th Acta Oncologica Symposium BiGART 2013, June 11-13, 2013, Aarhus, Denmark.
Chairman of the Session on Innovations and Targets at the 28th Annual Meeting of the European Society for Hyperthermic Oncology, June 19-22, 2013, Munich, Germany.
Chairman of the Session on Biological Developments at the 29th Annual Meeting of the European Society for Hyperthermic Oncology, June 11-14, 2014, Torino, Italy.
Chairman of the Session on Tumor Oxygenation: Impact on Cancer Therapy at the 60th Annual Meeting of the Radiation Research Society, September 21-24, 2014, Las Vegas, USA.
Chairman of a poster session at the Aarhus University Graduate School of Health PhD Day, January 23, 2015, Aarhus, Denmark.
Chairman of the Session on Radiosensitization at the 15th International Congress of Radiation Research, May 25-29, 2015, Kyoto, Japan.
Chairman of the Session on Radiobiology of Human Tumors: Guidance for Therapy at the 13th Acta Oncologica Symposium BiGART 2015, June 10-12, 2015, Aarhus, Denmark.
Chairman of the Biology Session at the 30th Annual Meeting of the European Society for Hyperthermic Oncology, June 24-26, 2015, Zurich, Switzerland.
Chairman of the Session on Hypoxia: Imaging, Detection and Significance at the 14th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, August 27-29, 2015, Vancouver, Canada.
Chairman of a poster session at the Aarhus University Graduate School of Health PhD Day, January 22, 2016, Aarhus, Denmark.
Chairman of the Session on Emerging Hyperthermia Biology at the 12th International Congress on Hyperthermic Oncology, April 11-15, 2016, New Orleans, USA.
Chairman of the Session on Imaging, Biomarkers and Therapeutic Prediction at the 15th International Workshop on the Tumor Microenvironment: Hypoxia, angiogenesis and vasculature, April 27-29, 2017, Miami, USA.
Chairman of the Poster Discussion Session on Radiobiological/Pre-clinical Studies at the 14th Acta Oncologica Symposium BiGART 2017, June 13-16, 2017, Aarhus, Denmark.
Replacement Chairman (substitute due to illness) of Educational Session 1 at the 31st Annual Meeting of the European Society for Hyperthermic Oncology, June 21-23, 2017, Athens, Greece.
Chairman of Oral Presentation Session 5 at the 31st Annual Meeting of the European Society for Hyperthermic Oncology, June 21-23, 2017, Athens, Greece

Invited lectures at meetings, congresses and symposia

"Lund Science Award" Lecture, at the 5th International Congress of Hyperthermic Oncology, August 1988, Kyoto, Japan.
NATO Advanced Research Workshop on Selective Activation of Drugs by Redox Processes, August 1989, Fermo, Italy.
The 10th Annual Euro¬pean Society for Hyperthermic Oncology Meeting, September 1989, Amsterdam, The Netherlands.
EORTC Radiotherapy Group Consensus Meeting on Tumour Hypoxia, December 1989, Leuven, Belgium.
COMAC-BME Workshop on Clinical Evaluation of Hyperthermia, February 1990, Copenhagen, Denmark.
ARCON Workshop on Accelerated Radiotherapy with Carbogen/Oxygen and Nicotinamide, June 1991, Gray Laboratory, England.
The 12th Annual European Society for Hyperthermic Oncology Meeting, June 1991, Bergen, Norway.
Workshop on Bioreductive Drugs, Sensitizers, Oxygen, and Radiation, October 1991, Vienna, Austria.
Symposium on Treatment Resistance, Danish Society for Medical Oncology, January 1992, Helsingør, Denmark.
The 40th Annual Radiation Research Society Meeting, March 1992, Salt Lake City, UT, USA.
The 6th International Congress of Hyperthermic Oncology, April 1992, Tucson, AZ, USA.
The 11th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September 1992, Malmö, Sweden.
Workshop on The Potential of NMR Spectroscopy for In Vivo Cancer Research, April 1993, Aarhus, Denmark.
The 2nd ARCON Workshop on Accelerated Radiotherapy with Carbogen and Nicotinamide, March 1994, Northwood, England.
The 2nd International Expert Meeting on Tumour Oxygenation, March 1994, Hamburg, Germany.
The 14th Annual European Society for Hyperthermia Oncology Meeting, June 1994, Amsterdam, The Netherlands. 
Symposium in Honour of Lars-Gunnar Larsson's 75th Birthday, June 1994, Umeå, Sweden.
The 13th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September 1994, Granada, Spain.
The 43rd Annual Radiation Research Society Meeting, April 1995, San Jose, CA, USA.
Symposium on Tumour Oxygenation and Radiotherapy, Academic Medical Center, February 1996, Amsterdam, The Netherlands.
The European Nuclear Medicine Congress, September 1996, Copenhagen, Denmark.
The 2nd International Conference on Redox Processes and Cancer: Molecular Biology and Therapeutics, April 1997, Banff, Alberta, Canada.
The 10th International Conference on Chemical Modifiers of Cancer Treatment, January 1998, Clearwater, FL, USA.
The 17th Annual North American Hyperthermia Society Meeting, April 1998, Louisville, KY, USA.
The Dr. Paul Janssen Medical Institute Symposium on Tumour Oxygenation, March 1999, Munich, Germany.
The 8th Symposium on the Medical Applications of Cyclotrons, May 1999, Turku, Finland.
The 18th Annual Meeting of the European Society for Hyperthermic Oncology, September 1999, Rotterdam, The Netherlands.
The Danish Society for Medical Oncology Annual Meeting, January 2000, Helsingør, Denmark.
The 19th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September 2000, Istanbul, Turkey.
The Annual Meeting of the Belgium Society for Cancer Research, January 2001, Brussels, Belgium.
The 18th North American Hyperthermia Society Annual Scientific Meeting, April 2001, San Juan, Puerto Rico.
Scandinavian Congress in Clinical Physiology and Nuclear Medicine, April 2001, Aarhus, Denmark.
The 4th Nordic Conference on Radiation Oncology, June 2001, Aarhus, Denmark.
The 1st ESTRO Workshop on Biology in Radiation Oncology, June 2001, Fuglsø, Denmark.
The XI Congress of the Spanish Association for Radiotherapy and Oncology, October 2001, Murcia, Spain.
The Danish Society for Biochemistry and Molecular Biology Symposium on From Gas to Gene: Molecular Mechanism of Oxygen Sensing in Health and Disease, February 2002, Copenhagen, Denmark.
The Dansk Selskab for Onkologi Annual Meeting, April 2002, Middlefart, Denmark.
The 49th Annual Radiation Research Society Meeting, April 2002, Reno, NV, USA.
The 1st International Conference on Vascular Targeting, June 2002, Boston, MA, USA.
The 8th International Workshop on the Tumor Microenvironment and its Impact on Cancer Therapies, May 2003, Miami, FL, USA.
The 2nd ESTRO Workshop on Biology in Radiation Oncology, June 2003, Nijmegen, The Netherlands.
The 21st Annual Meeting of the European Society for Hyperthermic Oncology, June 2003, Munich, Germany.
Annual Meeting for Young Oncologists, November 2003, Albertslund, Denmark.
The 9th International Congress on Hyperthermic Oncology, April, 2004, St. Louis, MO, USA.
The 2nd International Conference on Vascular Targeting, May 2004, Miami, FL, USA.
The 23rd Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September 2004, Amsterdam, The Netherlands.
The 1st Scandinavian Medical Educational Workshop, April 2005, Stockholm, Sweden.
The 1st European Society for Hyperthermic Oncology Educational Day, June, 2005, Graz, Austria.
The 24th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, October, 2006, Leipzig, Germany.
The 3rd European Society for Hyperthermic Oncology Educational Day, May, 2007, Prague, Czech Republic.
The 24th Annual Meeting of the European Society for Hyperthermic Oncology, May, 2007, Prague, Czech Republic.
The Association for Radiation Research Annual Meeting, April, 2008, Manchester, UK.
The 10th International Congress on Hyperthermic Oncology, April, 2008, Munich, Germany.
The 25th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, September, 2008, Göteborg, Sweden.
The International Conference on Tumor hypoxia and malignant progression, October, 2008, Kiev, Ukraine.
The European Union 6th Framework BioCare Project Consensus Meeting, December, 2008, Brussels, Belgium.
The 4th International Conference on Translational Research and pre-clinical Strategies in Radiation Oncology, March, 2009, Geneva, Switzerland.
The 5th European Society for Hyperthermic Oncology Educational Day, June, 2009, Verona, Italy.
The 25th Annual Meeting of the European Society for Hyperthermic Oncology, June, 2009, Verona, Italy.
The 15th Annual Meeting of the German Society for Radiooncology, June, 2009, Bremen, Germany.ViVox workshop: Tools for cell therapy, November, 2009, Aarhus, Denmark.
The Association for Radiation Research Annual Meeting, June 2010, Oxford, UK.
The International Conference on Tumor and Host: novel aspects of old problem, September 2010, Kiev, Ukraine.Thermal Workshop on RF Hotspots, March, 2011, Zurich, Switzerland.
Radiation Oncology in Prostate Cancer Conference, April, 2011, Munich, Germany.
The 7th Biennial Conference of the Indian Association of Hyperthermic Oncology and Medicine, February 2012, Indore, India.
The 5th International Conference on Translational Research and Pre-Clinical Strategies in Radiation Oncology, March, 2012, Geneva, Switzerland.
The 29th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, May, 2012, Barcelona, Spain.
The Annual Meeting of the Radiation Research Society, October, 2012, Puerto Rico.
The 2nd International Conference on Tumor Microenvironment and Cellular Stress: Signalling, Metabolism, Imaging and Therapeutic Targets, September, 2013, Corfu, Greece.
The European Society for Hyperthermic Oncology School on Hyperthermia & Thermal Ablation in Cancer Therapy, February, 2014, Huntsham, UK.
The 6th International Conference on Translational Research in Radiation Oncology, February, 2014, Geneva, Switzerland.
The 29th Annual Meeting of the European Society for Hyperthermic Oncology, June, 2014, Torino, Italy.
The Annual Meeting of the Radiation Research Society, September, 2014, Las Vegas, USA.
Workshop on Translational Research in Ion Beam Cancer Therapy, October 2014, Aarhus, Denmark.
The Winter School for Therapeutic Ultrasound, March 8-13, 2015, Les Houches, France.
The 3rd European Society for Therapeutic Radiology & Oncology Forum, April 24-28 2015, Barcelona, Spain.
The 15th International Congress of Radiation Research, May 25-29, 2015, Kyoto, Japan.
The 30th Annual Meeting of the European Society for Hyperthermic Oncology, June 24-27, 2015, Zurich, Switerland.
The Annual Meeting of the European Association for Nuclear Medicine, October 10-14, 2015, Hamburg, Germany.
The J.M. Brown Retirement Symposium, May 20-21, 2016, Palo Alto, California, USA.
The 4th International Conference on Tumor Microenvironment and Cellular Stress: Signalling, Metabolism, Imaging and Therapeutic Targets, June 5-10, 2016, Rhodes, Greece.
The Annual Meeting of the Radiation Research Society, October, 2016, Hawaii, USA.
The 31st Annual Meeting of the European Society for Hyperthermic Oncology, June 21-23, 2017, Athens, Greece.
The Winter School for Therapeutic Ultrasound, March 26-31, 2017, Les Houches, France.
National Meeting on Particle Therapy in Denmark, August 21-22, 2017, Aarhus, Denmark.

Other scientific activities

Member of the discussant panel for the Symposium on Clinical Implications for Moderate Hyperthermia at the 16th Annual Meeting of the North American Hyperthermia Society, May 1997, Providence, RI, USA.
Introducer for the Refresher Course "Tumour Microcirculation in Radiotherapy" given by Professor P.W. Vaupel at the 45th Annual Meeting of the Radiation Research Society, May 1997, Providence, RI, USA.
Abstract Reviewer for the 43rd Annual Meeting of the American Society for Therpeutic Radiology and Oncology, November 2001, San Fransisco, CA, USA.
Member of the Panel Discussion at the PTAC Workshop on MRI Methodology for the Pharmacodynamic Assessment of Antivascular and Antiangiogenic Agents, March 2002, London, England.
Member of the WHO Temperature Workshop, March 2002, Geneva, Switzerland.
Member of the Selection Committee for Best Oral Presentation at the Danish Society for Cancer Research Annual Meeting, May 2002, Vilvorde, Denmark.
Abstract Reviewer for the 45th Annual Meeting of the American Society for Therpeutic Radiology and Oncology, October 2003, Salt Lake City, Utah, USA.
Member of the Antivascular therapy taxonomy and terminology expert panel meeting, December 2003, London, UK.
Abstract Reviewer for the 46th Annual Meeting of the American Society for Therpeutic Radiology and Oncology, October 2004, Atlanta, GA, USA.
Member of the International Atomic Energy Agency Technical Meeting Committee August, 2004, Budapest, Hungary.
Abstract Reviewer for the 47th Annual Meeting of the American Society for Therpeutic Radiology and Oncology, October 2005, Denver, CO, USA.
Abstract Reviewer for the Annual Meetings of the Danish Association for Cancer Research, 2006-2008, Vilvorde, Denmark.
Abstract Reviewer for Biology and Physiology section of the 10th International Congress on Hyperthermic Oncology, April, 2008, Munich, Germany.
Introducer of the Award lecture given by Prof. Hans Skovgaard-Poulsen at the Danish Association for Cancer Research Annual Meeting, April, 2008, Vilvorde, Denmark.
Member of the Selection Committee for Best Poster Presentation at the Danish Association for Cancer Research Annual Meeting, May 2008, Vilvorde, Denmark.
Member of the Selection Committee for Best Biology Poster Presentation at the International Congress of Hyperthermic Oncology, August 2012, Kyoto, Japan.
Member of the Selection Committee for the ESHO Student Awards presented at the 28th Annual Meeting of the European Society for Hyperthermic Oncology, June 2013, Munich, Germany.
Member of the Selection Committee for the ESHO Student Awards presented at the 29th Annual Meeting of the European Society for Hyperthermic Oncology, June 2014, Torino, Italy.
Abstract Reviewer for the 3rd Biology-Guided Adaptive Radiotherapy Symposium, June 2015, Aarhus, Denmark.
Member of the Selection Committee for the ESHO Student Awards presented at the 30th Annual Meeting of the European Society for Hyperthermic Oncology, June 2015, Zurich, Switzerland.
Member of the Selection Committee for Best Poster Presentation at the Danish Association for Cancer Research Annual Meeting, April 2016, Vilvorde, Denmark.
Chairman of the external Scientific Advisory Board for the Cancer Research UK Imaging Centre, January 2017, Sutton, Surrey, UK.

Scientific meeting presentations

Presentations: 499 (with abstracts: 437; without abstracts: 62)
As presenting author: 242

Invited department seminars

M.R.C. Radiobiology Unit, Chilton, Oxon, England (December 1985).
Medical Biophysics Unit, B.C. Cancer Research Center, Vancouver, British Columbia, Canada (August 1986).
M.R.C. Clinical Oncology and Radiothe¬rapeutics Unit, Cambridge, England (Novem¬ber 1987).
C.R.C. Gray Laboratory, Mount Vernon Hospital, Northwood, England (November 1987).
Radiotherapy Research Unit, Institute of Cancer Research, Sutton, England (November 1987).
Dept. Radiation Oncology, University of Pennsyl¬vania, Philadel¬phia, PA, USA (April 1988).
Medical Biophysics Unit, B.C. Cancer Research Center, Vancouver, British Columbia, Canada (April 1988).
Dept. Radiology, Stanford University Medical Center, Stanford, CA, USA (April 1988).
Medical Biophysics Unit, B.C. Cancer Research Center, Vancouver, British Columbia, Canada (March 1989).
Joint Center for Radiation Therapy, Boston, MA, USA (June 1989).
C.R.C. Gray Laboratory, Mount Vernon Hospital, Northwood, England (December 1989).
C.R.C. Gray Laboratory, Mount Vernon Hospital, Northwood, England (December 1991).
Dept. Radiotherapy, University of Pisa, Pisa, Italy (January 1992).
Medical Biophysics Unit, B.C. Cancer Research Center, Vancouver, British Columbia, Canada (March 1992).
M.R.C. Clinical Oncology and Radiotherapeutics Unit, Cambridge, England (April 1993).
M.R.C. Radiobiology Unit, Chilton, Oxon, England (April 1993).
C.R.C. Gray Laboratory, Mount Vernon Hospital, Northwood, England (April 1993).
Dept. Ecogenetics, University of Lund, Lund, Sweden (January 1994).
Laboratory of Cellular Radiobiology, Gustave-Roussy Institute, Villejuif, France (February 1994).
Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA (April 1994).
Dept. Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA (April 1994).
Dept. Radiation Oncology, Duke University Medical Centre, Durham, NC, USA (November 1996).
Dept. Radiation Oncology, University of North Carolina, Chapel Hill, NC, USA (November 1996).
Dept. Radiation Oncology, University of Florida, Gainesville, FL, USA (November 1996).
Dept. Radiation Therapy, University of Essen, Essen, Germany (June 1997).
Matrix Pharmaceutical Inc., Fremont, CA, USA (April 1998).
Dept. Radiology, Washington University School of Medicine, St. Louis, MO, USA (April 1998).
Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, England (August 1998).
Dept. Radiation Oncology, Lund University Hospital, Lund, Sweden (September 1998).
Dept. Pharmacology, University of Aarhus, Aarhus, Denmark (December 2000).
Dept. Pharmacology, University of Aarhus, Aarhus, Denmark (April 2003).
Dept. Biochemistry and Immunology, St. George’s Hospital Medical School, London, England (February 2005).
Patterson Institute, University of Manchester, Manchester, UK (October 2005).
Dept. Radiation Oncology, University of Florida, Gainesville, FL, USA (August 2010).
Klinikum rechts der Isar, Technical University in Munich, Munich, Germany (August 2011).
The Institute of Cancer Research, Sutton, Surrey, UK (January 2017).
Dept. Radiation Oncology, Academic Medical Center, University of Amsterdam, The Netherlands (March 2017).

Scientific journal involvements

ASSOCIATED EDITOR:
International Journal of Radiation Biology (2012-)
International Journal of Radiation Oncology Biology Physics (1995-2011)
Acta Oncologica (1992-)

MEMBER OF EDITORIAL BOARD:
Journal of Cancer Research and Therapeutics (2011-2016)
International Journal of Hyperthermia (1993-)

GUEST EDITORIAL MEMBER:
Experimental Oncology (1996-2017)

JOURNAL GUEST EDITOR:
Acta Oncologica (1995): 34: (3). Special issue dedicated to the International Workshop on the Tumor Microenvironment - its characterization, modification and clinical implications

International Journal of Hyperthermia: 24: (1). Special issue on Cellular and vascular effects of hyperthermia (2008)

International Journal of Hyperthermia (2010) 26: (3). Special issue on Tumour perfusion and Associated physiology: characterisation and significance for hyperthermia (2010)

MANUSCRIPT REVIEWER:
Over 500 peer reviewed for 65 International Journals

Memberships

Association for Radiation Research
Radiation Research Society
European Society for Hyperthermic Oncology
Society for Experimental Biology and Medicine
British Association for Cancer Research
European Society for Therapeutic Radiology and Oncology
Danish Society for Cancer Research
International Society on Oxygen Transport to Tissue
American Association for Cancer Research
European Society for Radiation Biology
European Association for Cancer Research
American Society for Therapeutic Radiology and Oncology

Publications

Refinement of an established procedure and its application for identification of hypoxia in prostate cancer xenografts

Elming, P. B., Wittenborn, T. R., Busk, M., Sørensen, B. S., Thomsen, M. B. H., Strandgaard, T., Dyrskjøt, L., Nielsen, S. & Horsman, M. R., Jun 2021, In: Cancers. 13, 11, 2602.

Does the combination of hyperthermia with low LET (linear energy transfer) radiation induce anti-tumor effects equivalent to those seen with high LET radiation alone?

Elming, P. B., Sørensen, B. S., Spejlborg, H., Overgaard, J. & Horsman, M. R., 2021, In: International Journal of Hyperthermia. 38, 1, p. 105-110 6 p.

Proton scanning and X-ray beam irradiation induce distinct regulation of inflammatory cytokines in a preclinical mouse model

Nielsen, S., Bassler, N., Grzanka, L., Swakon, J., Olko, P., Horsman, M. R. & Sørensen, B. S., Oct 2020, In: International Journal of Radiation Biology. 96, 10, p. 1238-1244 7 p.

Tumors resistant to checkpoint inhibitors can become sensitive after treatment with vascular disrupting agents

Horsman, M. R., Wittenborn, T. R., Nielsen, P. S. & Elming, P. B., Jul 2020, In: International Journal of Molecular Sciences. 21, 13, p. 1-14 14 p., 4778.

Molecular and biological rationale of hyperthermia as radio- and chemosensitizer

Oei, A. L., Kok, H. P., Oei, S. B., Horsman, M. R., Stalpers, L. J. A., Franken, N. A. P. & Crezee, J., 2020, In: Advanced Drug Delivery Reviews. 163-164, p. 84-97 14 p.

Dual-tracer PET of viable tumor volume and hypoxia for identification of necrosis-containing radio-resistant Sub-volumes

Busk, M., Horsman, M. R., Overgaard, J. & Jakobsen, S., 2019, In: Acta Oncologica. 58, 10, p. 1476-1482 7 p.

Reliability of blood lactate as a measure of exercise intensity in different strains of mice during forced treadmill running

Lønbro, S., Wiggins, J. M., Wittenborn, T., Elming, P. B., Rice, L., Pampo, C., Lee, J. A., Siemann, D. W. & Horsman, M. R., 2019, In: PLOS ONE. 14, 5, 15 p., e0215584.

APD-Containing Cyclolipodepsipeptides Target Mitochondrial Function in Hypoxic Cancer Cells

Jacobsen, K. M., Villadsen, N. L., Tørring, T., Nielsen, C. B., Salomón, T., Nielsen, M. M., Tsakos, M., Sibbersen, C., Scavenius, C., Nielsen, R., Christensen, E. I., Guerra, P. F., Bross, P., Pedersen, J. S., Enghild, J. J., Johannsen, M., Frøkiær, J., Overgaard, J., Horsman, M. R., Busk, M. & Poulsen, T. B., Nov 2018, In: Cell Chemical Biology. 25, 11, p. 1337-1349.e12 13 p.

Enhancing the radiation response of tumors but not early or late responding normal tissues using a vascular disrupting agent

Horsman, M. R., Nov 2017, In: Acta Oncologica. 56, 11, p. 1634-1638 5 p.

Hypoxia positron emission tomography imaging: combining information on perfusion and tracer retention to improve hypoxia specificity

Busk, M., Munk, O. L., Jakobsen, S. S. & Horsman, M. R., Nov 2017, In: Acta Oncologica. 56, 11, p. 1583-1590 8 p.

Relative biological effectiveness (RBE) and distal edge effects of proton radiation on early damage in vivo

Sørensen, B. S., Bassler, N., Nielsen, S., Horsman, M. R., Grzanka, L., Spejlborg, H., Swakoń, J., Olko, P. & Overgaard, J., Nov 2017, In: Acta Oncologica. 56, 11, p. 1387-1391 5 p.

Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer

Siemann, D. W., Chaplin, D. J. & Horsman, M. R., 14 Sep 2017, In: Cancer Investigation. 35, 8, p. 519-534 16 p.

Results from (11)C-metformin-PET scans, tissue analysis and cellular drug-sensitivity assays questions the view that biguanides affects tumor respiration directly

Iversen, A. B., Horsman, M. R., Jakobsen, S., Jensen, J. B., Garm, C., Jessen, N., Breining, P., Frøkiær, J. & Busk, M., 25 Aug 2017, In: Scientific Reports. 7, 1, p. 9436 13 p., 9436.

FDG-PET reproducibility in tumor-bearing mice: comparing a traditional SUV approach with a tumor-to-brain tissue ratio approach

Busk, M., Munk, O. L., Jakobsen, S., Frøkiær, J., Overgaard, J. & Horsman, M. R., May 2017, In: Acta oncologica (Stockholm, Sweden). 56, 5, p. 706-712

Targeting therapy-resistant cancer stem cells by hyperthermia

Oei, A. L., Vriend, L. E. M., Krawczyk, P. M., Horsman, M. R., Franken, N. A. P. & Crezee, J., 2017, In: International Journal of Hyperthermia. 33, 4, p. 419-427 12 p.

The potential of hyperpolarized (13)C magnetic resonance spectroscopy to monitor the effect of combretastatin based vascular disrupting agents

Iversen, A. B., Busk, M., Bertelsen, L. B., Laustsen, C., Munk, O. L., Nielsen, T., Wittenborn, T. R., Bussink, J., Lok, J., Stødkilde-Jørgensen, H. & Horsman, M. R., 2017, In: Acta oncologica (Stockholm, Sweden). 56, p. 1-8 8 p.

Simulation of heterogeneous molecular delivery in tumours using μCT reconstructions and MRI validation

Wittenborn, T. R., Nielsen, T., Thomsen, J. S., Horsman, M. R. & Nygaard, J. V., 26 Aug 2016, In: Microvascular Research. 108, p. 69-74 6 p.

The impact of hypoxia and its modification of the outcome of radiotherapy

Horsman, M. R. & Overgaard, J., 16 Aug 2016, In: Journal of Radiation Research. 57, 1, p. 90-98 9 p.

Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L

Parker, E. N., Song, J., Kishore Kumar, G. D., Odutola, S. O., Chavarria, G. E., Charlton-Sevcik, A. K., Strecker, T. E., Barnes, A. L., Sudhan, D. R., Wittenborn, T. R., Siemann, D. W., Horsman, M. R., Chaplin, D. J., Trawick, M. L. & Pinney, K. G., 1 Nov 2015, In: Bioorganic & Medicinal Chemistry. 23, 21, p. 6974-6992 19 p.

Photoelectron Spectra and Electronic Structures of the Radiosensitizer Nimorazole and Related Compounds

Feketeová, L., Plekan, O., Goonewardane, M., Ahmed, M., Albright, A. L., White, J., O'Hair, R. A. J., Horsman, M. R., Wang, F. & Prince, K. C., 1 Oct 2015, In: Journal of Physical Chemistry Part A: Molecules, Spectroscopy, Kinetics, Environment and General Theory. 119, 39, p. 9986-95 10 p.

Hyperpolarized magnetic resonance spectroscopy for assessing tumor hypoxia

Iversen, A. B., Ringgaard, S., Laustsen, C., Stødkilde-Jørgensen, H., Bentzen, L., Busk, M. & Horsman, M. R., 4 Sep 2015, In: Acta Oncologica. p. 1393-1398 6 p.

Modulation of the tumor vasculature and oxygenation to improve therapy

Siemann, D. W. & Horsman, M. R., Sep 2015, In: Pharmacology & Therapeutics. 153, 9, p. 107-24 18 p.

The usability of a 15-gene hypoxia classifier as a universal hypoxia profile in various cancer cell types

Sørensen, B. S., Knudsen, A. B., Wittrup, C. F., Nielsen, S., Aggerholm-Pedersen, N., Busk, M., Horsman, M., Høyer, M., Bouchelouche, P. N., Overgaard, J. & Alsner, J., Sep 2015, In: Radiotherapy & Oncology. 116, 3, p. 346-51 6 p.

A tissue-engineered therapeutic device inhibits tumor growth in vitro and in vivo

Sun, M., Wang, M., Chen, M., Dagnaes-Hansen, F., Le, D. Q. S., Baatrup, A., Horsman, M. R., Kjems, J. & Bünger, C., May 2015, In: Acta Biomaterialia. 18, p. 21-29 9 p.

Therapeutic potential of using the vascular disrupting agent OXi4503 to enhance mild temperature thermoradiation

Horsman, M. R., May 2015, In: International Journal of Hyperthermia. 31, 5, p. 453-9 7 p.

Uniform Combretastatin-induced Effect on Monocytes and Neutrophils in Peripheral Blood but Not in Tumors

Bohn, A. B., Brems-Eskildsen, A. S., Møller, B. K. & Horsman, M. R., May 2015, In: Anticancer Research. 35, 5, p. 2559-64 6 p.

Relative biological effectiveness of carbon ions for tumor control, acute skin damage and late radiation-induced fibrosis in a mouse model

Sørensen, B. S., Horsman, M. R., Alsner, J., Overgaard, J., Durante, M., Scholz, M., Friedrich, T. & Bassler, N., 2015, In: Acta Oncologica. 54, 9, p. 1623-1630 8 p.

Simultaneous Hypoxia and Low Extracellular pH Suppress Overall Metabolic Rate and Protein Synthesis In Vitro

Sørensen, B. S., Busk, M., Overgaard, J., Horsman, M. R. & Alsner, J., 2015, In: PLOS ONE. 10, 8, 14 p., e0134955.

Targeting tumour hypoxia to improve outcome of stereotactic radiotherapy

Wittenborn, T. R. & Horsman, M. R., 2015, In: Acta Oncologica. 54, 9, p. 1385-92 8 p.

Effect of radiation on cell proliferation and tumor hypoxia in HPV-positive head and neck cancer in vivo models

Sørensen, B. S., Busk, M., Horsman, M. R., Alsner, J., Overgaard, J., Kyle, A. H. & Minchinton, A. I., Nov 2014, In: Anticancer Research. 34, 11, p. 6297-304 8 p.

In vivo bio-distribution and homing of endothelial outgrowth cells in a tumour model

Bertelsen, L. B., Hagensen, M., Busk, M., Zhang, R., Knudsen, A. S., Nielsen, N., Falborg, L., Møller, B. K., Horsman, M. R. & Stødkilde-Jørgensen, H., 1 Aug 2014, In: Nuclear Medicine and Biology. p. 848-855 8 p.

Formation of radical anions of radiosensitizers and related model compounds via electrospray ionization

Feketeová, L., Albright, A. L., Sørensen, B. S., Horsman, M. R., White, J., O'Hair, R. A. J. & Bassler, N., 15 May 2014, In: International Journal of Mass Spectrometry. 365-366, p. 56-63 8 p.

Accumulation of nano-sized particles in a murine model of angiogenesis

Wittenborn, T. R., Larsen, E. K. U., Nielsen, T., Rydtoft, L. M., Hansen, L., Nygaard, J. V., Vorup-Jensen, T., Kjems, J., Horsman, M. R. & Nielsen, N. C., 10 Jan 2014, In: Biochemical and Biophysical Research Communications. 443, 2, p. 470-6 7 p.

A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor models

Bohn, A. B., Wittenborn, T., Brems-Eskildsen, A. S., Laurberg, T., Bertelsen, L. B., Nielsen, T., Stødkilde-Jørgensen, H., Møller, B. K. & Horsman, M. R., 2014, In: PLOS ONE. 9, 10, p. e110091

Treatment with a vascular disrupting agent does not increase recruitment of indium labelled human endothelial outgrowth cells in an experimental tumour model

Bertelsen, L. B., Bohn, A. B., Shen, Y. Y., Falborg, L., Stødkilde-Jørgensen, H. & Horsman, M. R., 2014, In: B M C Cancer. 14, p. 903 9 p.

Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy

Iversen, A. B., Busk, M. & Horsman, M. R., Oct 2013, In: Acta Oncologica. 52, 7, p. 1320-6 7 p.

Relevance of hypoxia in radiation oncology: pathophysiology, tumor biology and implications for treatment

Busk, M. & Horsman, M. R., Sep 2013, In: Quarterly Journal of Nuclear Medicine and Molecular Imaging. 57, 3, p. 219-234 16 p.

Ultra-high field (1)H magnetic resonance imaging approaches for acute hypoxia

Nielsen, T., Nielsen, N. C., Holm, T. H., Ostergaard, L., Horsman, M. R. & Busk, M., 30 Aug 2013, In: Acta oncologica (Stockholm, Sweden). 52, 7, p. 1287-1292

Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells

Sørensen, B. S., Busk, M., Olthof, N., Speel, E-J., Horsman, M. R., Alsner, J. & Overgaard, J., 13 Aug 2013, In: Radiotherapy & Oncology. 108, 3, p. 500-505 6 p.

The relationship between tumor blood flow, angiogenesis, tumor hypoxia, and aerobic glycolysis

Østergaard, L., Tietze, A., Nielsen, T., Drasbek, K. R., Mouridsen, K., Jespersen, S. N. & Horsman, M. R., 13 Jun 2013, In: Cancer Research. 73, 18, p. 5618-5624 7 p.

Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo

Horsman, M. R., Christensen, K. L. & Overgaard, J., Apr 2013, In: International Journal of Hyperthermia. 5, 2, p. 123-36 14 p.

Peritoneal macrophages mediated delivery of chitosan/siRNA nanoparticle to the lesion site in a murine radiation-induced fibrosis model

Nawroth, I., Alsner, J., Deleuran, B. W., Dagnæs-Hansen, F., Yang, C., Horsman, M. R., Overgaard, J., Howard, K., Kjems, J. & Gao, S., 1 Jan 2013, In: Acta Oncologica. 52, 8, p. 1730-1738 9 p.

PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice

Busk, M., Mortensen, L. S., Nordsmark, M., Overgaard, J., Jakobsen, S., Hansen, K. V., Theil, J., Kallehauge, J., D'Andrea, F. P., Steiniche, T. & Horsman, M. R., Jan 2013, In: European Journal of Nuclear Medicine and Molecular Imaging. 40, 2, p. 186-97 12 p.

PET imaging of tumor hypoxia using 18F-labeled pimonidazole

Busk, M., Jakobsen, S., Horsman, M. R., Mortensen, L. S., Iversen, A. B., Overgaard, J., Nordsmark, M., Ji, X., Lee, D. Y. & Raleigh, J. R., 2013, In: Acta Oncologica. 52, 7, p. 1300-1307 8 p.

Tumour microenvironment and radiation response in sarcomas originating from tumourigenic human mesenchymal stem cells

D'Andrea, F. P., Safwat, A. A., Burns, J. S., Kassem, M., Horsman, M. R. & Overgaard, J., Jun 2012, In: International Journal of Radiation Biology. 88, 6, p. 457-465 9 p.

Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging

Nielsen, T., Bentzen, L., Pedersen, M. N., Tramm, T., Rijken, P. F. J. W., Bussink, J., Horsman, M. R. & Østergaard, L., 2012, In: Clinical Cancer Research. 18, 23, p. 6469-77 9 p.

Imaging hypoxia to improve radiotherapy outcome

Horsman, M. R., Mortensen, L. S., Petersen, J. B., Busk, M. & Overgaard, J., 2012, In: Nature Reviews. Clinical Oncology. 9, 12, p. 674-87 14 p.

Initial evaluation of the antitumour activity of KGP94, a functionalized benzophenone thiosemicarbazone inhibitor of cathepsin L

Chavarria, G. E., Horsman, M. R., Arispe, W. M., Kumar, G. D. K., Chen, S-E., Strecker, T. E., Parker, E. N., Chaplin, D. J., Pinney, K. G. & Trawick, M. L., 2012, In: European Journal of Medicinal Chemistry. 58, p. 568-72 5 p.

The vascular-disrupting agent, combretastatin-A4-phosphate, enhances neurogenic vasoconstriction in rat small arteries

Su, J., Laursen, B. E., Eskildsen-Helmond, Y., Horsman, M. R. & Simonsen, U., 2012, In: European Journal of Pharmacology. p. 104-111 8 p.

Treatment with the vascular disrupting agent Combretastatin is associated with impaired AQP2 trafficking and increased urine output

Bohn, A. B., Norregaard, R., Stødkilde-Jørgensen, L., Wang, Y., Bertelsen, L. B., Fenton, R. A., Matchkov, V. V., Bouzinova, E. V., Horsman, M. R., Frokiaer, J. & Stødkilde-Jørgensen, H., 2012, In: American Journal of Physiology: Regulatory, Integrative and Comparative Physiology. p. R186-R198 13 p.

Tumourigenicity and radiation resistance of mesenchymal stem cells

D'Andrea, F. P., Horsman, M. R., Kassem, M., Overgaard, J. & Safwat, A. A., 2012, In: Acta Oncologica. 51, 5, p. 669-679 11 p.

Ultra-High-Field DCE-MRI of Angiogenesis in a Novel Angiogenesis Mouse Model

Wittenborn, T., Nielsen, T., Nygaard, J. V., Larsen, E. K. U., Thim, T., Rydtoft, L. M., Vorup-Jensen, T., Kjems, J., Nielsen, N. C., Horsman, M. R. & Falk, E., 2012, In: Journal of Magnetic Resonance Imaging. 35, 3, p. 703-710 7 p.

Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation

Bertelsen, L. B., Shen, Y. Y., Nielsen, T., Stødkilde-Jørgensen, H., Lloyd, G. K., Siemann, D. W. & Horsman, M. R., Nov 2011, In: International Journal of Radiation Biology. 87, 11, p. 1126-1134 9 p.

Cancer stem cell overexpression of nicotinamide N-methyltransferase enhances cellular radiation resistance

D'Andrea, F. P., Safwat, A. A., Kassem, M., Gautier, L., Overgaard, J. & Horsman, M. R., Jun 2011, In: Radiotherapy & Oncology. 99, 3, p. 373-378 6 p.

In vivo Identification and Specificity assessment of mRNA markers of hypoxia in human and mouse tumors

Busk, M., Toustrup, K., Soerensen, B. S., Alsner, J., Horsman, M. R., Jakobsen, S. & Overgaard, J., 9 Feb 2011, In: B M C Cancer. 11, 1, p. 63

Accessing radiation response using hypoxia PET imaging and oxygen sensitive electrodes: a preclinical study

Mortensen, L. S., Busk, M., Nordsmark, M., Jakobsen, S., Theil, J., Overgaard, J. & Horsman, M. R., 2011, In: Radiotherapy & Oncology. 99, 3, p. 418-23 6 p.

Combretastatin-induced hypertension and the consequences for its combination with other therapies

Busk, M., Bohn, A. B., Skals, M., Wang, T. & Horsman, M. R., 2011, In: Vascular Pharmacology. 54, 1-2, p. 13-17 5 p.

Inhibition of tumor lactate oxidation: consequences for the tumor microenvironment

Busk, M., Walenta, S., Mueller-Klieser, W., Steiniche, T., Jakobsen, S., Horsman, M. R. & Overgaard, J., 2011, In: Radiotherapy & Oncology. p. 404-11 8 p.

Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival

Offersen, B. V., Knap, M. M., Horsman, M. R., Verheijen, J., Hanemaaijer, R. & Overgaard, J., 1 Nov 2010, In: Acta Oncologica. 49, 8, p. 1283-7 5 p.

Identifying pH independent hypoxia induced genes in human squamous cell carcinomas in vitro

Sørensen, B. S., Toustrup, K., Horsman, M. R., Overgaard, J. & Alsner, J., Oct 2010, In: Acta Oncologica. 49, 7, p. 895-905 11 p.

Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan

Hasselbalch, B., Eriksen, J. G., Broholm, H., Christensen, I. J., Grunnet, K., Horsman, M. R., Poulsen, H. S., Stockhausen, M-T. & Lassen, U., 1 Aug 2010, In: Acta Pathologica Microbiologica et Immunologica Scandinavica. 118, 8, p. 585-94 10 p.

Tumour perfusion and associated physiology: characterization and significance for hyperthermia

Vaupel, P. & Horsman, M. R., 1 Jan 2010, In: International Journal of Hyperthermia. 26, 3, p. 209-10 2 p.

Assessing hypoxia in animal tumor models based on pharmocokinetic analysis of dynamic FAZA PET

Busk, M., Munk, O. L., Jakobsen, S., Wang, T., Skals, M., Steiniche, T., Horsman, M. R. & Overgaard, J., 2010, In: Acta Oncologica. 49, 7, p. 922-33 11 p.

Biodistribution of 99mTc-HYNIC-lactadherin in mice - a potential tracer for visualizing apoptosis in vivo

Falborg, L., Waehrens, L. N., Alsner, J., Bluhme, H., Frøkiaer, J., Heegaard, C. W., Horsman, M. R., Rasmussen, J. T. & Rehling, M., 2010, In: Scandinavian Journal of Clinical & Laboratory Investigation. 70, 3, p. 209-16 7 p.

Imaging tumour physiology and vasculature to predict and assess response to heat

Hokland, S., Nielsen, T., Busk, M. & Horsman, M. R., 2010, In: International Journal of Hyperthermia. 26, 3, p. 264-72 8 p.

NPI-2358 Rapidly Inhibit the Blood Flow in Tumour Treatment by Analyzing Dynamic Contrast Enhanced Magnetic Resonance Imaging Parameters

Shen, Y. Y., Liu, C-X., Bertelsen, L. B., Nielsen, T., Horsman, M. R. & Stødkilde-Jørgensen, H., 2010, In: China Journal of Cancer Prevention and Treatment. 7, p. 488-490 3 p.

Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates

Nielsen, T., Murata, R., Maxwell, R. J., Stødkilde-Jørgensen, H., Østergaard, L., Ley, C. D., Kristjansen, P. E. G. & Horsman, M. R., 2010, In: Acta Oncologica. 49, 7, p. 906-13 7 p.

Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast?

Busk, M., Horsman, M. R., Jakobsen, S., Hansen, K. V., Bussink, J., van der Kogel, A. & Overgaard, J., Sep 2009, In: Radiotherapy & Oncology. 92, 3, p. 429-436 7 p.

A Novel in Vivo Angiogenesis Mouse Model

Wittenborn, T., Nygaard, J. V., Horsman, M. R., Vorup-Jensen, T., Kjems, J., Thim, T., Nielsen, T., Larsen, E. K. U. & Falk, E., 2009, In: Arteriosclerosis, Thrombosis, and Vascular Biology. 7

Proteins upregulated by mild and severe hypoxia in squamous cell carcinomas in vitro identified by proteomics

Sørensen, B. S., Horsman, M. R., Vorum, H., Honoré, B., Overgaard, J. & Alsner, J., 2009, In: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 92, 3, p. 443-9 6 p.

Size-Dependent Accumulation of PEGylated Silane-Coated Magnetic Iron Oxide Nanoparticles in Murine Tumors

Larsen, E. K. U., Nielsen, T., Wittenborn, T., Birkedal, H., Vorup-Jensen, T., Jakobsen, M. H., Østergaard, L., Horsman, M. R., Besenbacher, F., Howard, K. A. & Kjems, J., 2009, In: A C S Nano. 3, 7, p. 1947-51 5 p.

Vascular targeted therapies in oncology

Siemann, D. W. & Horsman, M. R., 2009, In: Cell and Tissue Research. 335, 1, p. 241-8 7 p.

Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage

Busk, M., Horsman, M. R., Jakobsen, S., Bussink, J., van der Kogel, A. & Overgaard, J., Dec 2008, In: European Journal of Nuclear Medicine and Molecular Imaging. 35, 12, p. 2294-303 10 p.

Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia

Busk, M., Horsman, M. R., Kristjansen, P. E. G., van der Kogel, A. J., Bussink, J. & Overgaard, J., 15 Jun 2008, In: International Journal of Cancer. 122, 12, p. 2726-34 9 p.

Imaging Hypoxia in Xenografted and Murine Tumors with 18F-Fluoroazomycin Arabinoside: A Comparative Study Involving microPET, Autoradiography, pO2-Polarography, and Fluorescence Microscopy

Busk, M., Horsman, M. R., Jakobsen, S., Keiding, S., van der Kogel, A. J., Bussink, J. & Overgaard, J., 15 Mar 2008, In: International Journal of Radiation Oncology, Biology, Physics. 70, 4, p. 1202-12 11 p.

Angiogenesis and vascular targeting: Relevance for hyperthermia.

Horsman, M. R., 2008, In: International Journal of Hyperthermia. 24, 1, p. 57-65 8 p.

Cellular and vascular effects of hyperthermia

Milani, V. & Horsman, M. R., 2008, In: International Journal of Hyperthermia. 24, 1, p. 1-2 1 p.

Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole

Murata, R., Tsujitani, M. & Horsman, M. R., 2008, In: Radiotherapy & Oncology. 87, 3, p. 331-8 7 p.

Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients

Nielsen, T., Murata, R., Maxwell, R. J., Stødkilde-Jørgensen, H., Østergaard, L. & Horsman, M. R., 2008, In: International Journal of Radiation Oncology, Biology, Physics. 70, 3, p. 859-66 8 p.

Resolution in PET hypoxia imaging: voxel size matters

Busk, M., Horsman, M. R. & Overgaard, J., 2008, In: Acta Oncologica. 47, 7, p. 1201-10 10 p.

Segmentation of dynamic contrast enhanced magnetic resonance imaging data

Nielsen, T., Mouridsen, K., Maxwell, R. J., Stødkilde-Jørgensen, H., Østergaard, L. & Horsman, M. R., 2008, In: Acta Oncologica. 47, 7, p. 1265-70 5 p.

The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours.

Chen, G., Horsman, M. R., Pedersen, M., Pang, Q. & Stødkilde-Jørgensen, H., 2008, In: Acta Oncologica. 47, 6, p. 1071-6 5 p.

The impact of hypoxia on the activity of lactate dehydrogenase in two different pre-clinical tumour models

Lukacova, S., Sørensen, B., Alsner, J., Overgaard, J. & Horsman, M., 2008, In: Acta Oncologica. 47, 5, p. 941-47 7 p.

Hyperthermia: a potent enhancer of radiotherapy

Horsman, M. R. & Overgaard, J., Aug 2007, In: Clinical Oncology. 19, 6, p. 418-426 9 p.

Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients

Nordsmark, M., Eriksen, J. G., Gebski, V., Alsner, J., Horsman, M. R. & Overgaard, J., Jun 2007, In: Radiotherapy & Oncology. 83, 3, p. 389-397 9 p.

Hypoxia induced expression of endogenous markers in vitro is highly influenced by pH

Sørensen, B. S., Alsner, J., Overgaard, J. & Horsman, M. R., Jun 2007, In: Radiotherapy & Oncology. 83, 3, p. 362-366

Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure

Ley, C. D., Horsman, M. R. & Kristjansen, P. E. G., 2007, In: NeoPlasia. 9, 2, p. 108-112

The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitisation

Hokland, S. & Horsman, M. R., 2007, In: International Journal of Hyperthermia. 23, 7, p. 599-606

Strain and tumour specific variations in the effect of hypoxia on osteopontin levels in experimental models

Lukácová, S., Overgaard, J., Alsner, J. & Horsman, M. R., Aug 2006, In: Radiotherapy & Oncology. 80, 2, p. 165-171 7 p.

Current development status of small-molecule vascular disrupting agents

Chaplin, D. J., Horsman, M. R. & Siemann, D. W., 2006, In: Current Opinion in Investigational Drugs. 7, 6, p. 522-8 7 p.

Hyperthermia is effective in improving clinical radiotherapy results: in response to Drs. Van der Zee and van Rhoon

Horsman, M. R., 2006, In: International Journal of Radiation Oncology, Biology, Physics. 66, p. 634

Is expression of the epidermal growth factor receptor related to hypoxia in squamous cell carcinomas of the head and neck - an evaluation of the DAHANCA 5 study

Eriksen, J. G., Nordsmark, M., Alsner, J., Horsman, M. R., Steinicke, T. & Overgaard, J., 2006, Radiother Oncol. 78 (Suppl.1) ed. p. S38 1 p.

Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies

Horsman, M. R. & Siemann, D. W., 2006, In: Cancer Res.. 66, p. 11520-11539

Preclinical studies in murine tumours to elucidate the role of serum osteopontin as an endogenous marker of hypoxia

Lukacova, S., Khalil, A. A., Overgaard, J., Alsner, J. & Horsman, M. R., 2006, Radiother. Oncol.. 78 (Suppl.1) ed. p. S31 1 p.

Radiation administered as a large single dose or in a fractionated schedule: Role of the tumour vasculature as a target for influencing response

Horsman, M. R., Nielsen, T., Østergaard, L. & Overgaard, J., 2006, In: Acta Oncologica. 45, 7, p. 876-80 5 p.

The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS

Breidahl, T., Nielsen, F. U., Stødkilde-Jørgensen, H., Maxwell, R. & Horsman, M. R., 2006, In: Acta. Oncol.. 45, 3, p. 306-316 10 p.

Tissue physiology and the response to heat

Horsman, M. R., 2006, In: Int. J. Hyperthermia. 22, p. 197-203

Tumor radiosensitizers - current status of development of various approaches: Report of an International Atomic Energy Agency meeting

Horsman, M. R., Bohm, L., Margison, G. P., Milas, L., Rosier, J-F., Safrany, G., Selzer, E., Verheij, M. & Hendry, J. H., 2006, In: International Journal of Radiation Oncology, Biology, Physics. 64, p. 551-561

Tumour hypoxia - a characteristic feature with a complex molecular background

Eriksen, J. G. & Horsman, M. R., 2006, In: Radiother. Oncol.. 81, p. 119-121

Relationship between radiobiological hypoxia in a C3H mouse mammary carcinoma and osteopontin levels in mouse serum

Lukácová, S., Khalil, A. A., Overgaard, J., Alsner, J. & Horsman, M. R., Dec 2005, In: International Journal of Radiation Biology. 81, 12, p. 937-944 8 p.

Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: Results from the DAHANCA 5 randomised double-blind placebo-controlled trial

Overgaard, J., Eriksen, J. G., Nordsmark, M., Alsner, J. & Horsman, M. R., Oct 2005, In: Lancet Oncology. 6, 10, p. 757-764 8 p.

Influence of oxygen concentration and pH on expression of hypoxia induced genes

Sørensen, B. S., Hao, J., Overgaard, J., Vorum, H., Honore, B., Alsner, J. & Horsman, M. R., Aug 2005, In: Radiotherapy & Oncology. 76, 2, p. 187-193 7 p.

Intravascular contrast agent-enhanced MRI measuring contrast clearance and tumor blood volume and the effects of vascular modifiers in an experimental tumor

Bentzen, L., Vestergaard-Poulsen, P., Nielsen, T., Overgaard, J., Bjørnerud, A., Briley-Saebø, K., Horsman, M. R. & Østergaard, L., 15 Mar 2005, In: International Journal of Radiation Oncology, Biology, Physics. 61, 4, p. 1208-15 8 p.

Differentiation and definition of vascular-targeted therapies

Siemann, D. W., Bibby, M. C., Dark, G. G., Dicker, A. P., Eskens, F. A. L. M., Horsman, M. R., Marmé, D. & LoRusso, P. M., 2005, In: Clinical Cancer Research. 11, 2 Pt 1, p. 416-420

Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode pO2 measurements in murine tumors

Sørensen, M., Horsman, M. R., Cumming, P., Munk, O. L. & Keiding, S., 2005, In: International Journal of Radiation Oncology, Biology, Physics. 62, 3, p. 854-861

Evaluation of anti-vascular therapy with texture analysis

Chen, G., Jespersen, S., Pedersen, M., Pang, Q., Horsman, M. R. & Stødkilde-Jørgensen, H., 2005, In: Anticancer Res. 25, 5, p. 3399-3405 7 p.

Experience with mouse hepatitis virus sanitation in three transplantable murine tumour lines

Dagnæs-Hansen, F. & Horsman, M. R., 2005, In: Lab Anim. 39, 4, p. 394-399

Influence of oxygen concentration and pH on expression of hypoxia induced genes

Sørensen, B. S., Hao, J., Overgaard, J., Alsner, J. & Horsman, M. R., 2005, Proceedings of the 9th International Wolfsberg Meeting on Molecular Radiation Biology / Oncology. 6 ed. p. 75 1 p.

Intravenous administration of Gd-DTPA prior to DWI does not affect the apparent diffusion constant

Chen, G., Jespersen, S., Pedersen, M., Qi, P., Horsman, M. R. & Stødkilde-Jørgensen, H., 2005, In: Magn Reson Imaging. 23, 5, p. 685-689 5 p.

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations

Leach, M. O., Brindle, K. M., Evelhoch, J. L., Griffiths, J. R., Horsman, M. R., Jackson, A., Jayson, C. G., Judson, I. R., Knopp, M. V., Maxwell, R. J., McIntyre, D., Padhani, A. R., Price, P., Rathbone, R., Rustin, G. J., Tofts, P. S., Tozer, G. M., Vennart, W., Waterton, J. C., Williams, S. R. & Workman, P., 2005, In:   Br. J. Cancer. 92, 9, p. 1599-1610

Vascular-targeting therapies for treatment of malignant disease

Siemann, D. W., Chaplin, D. J. & Horsman, M. R., 15 Jun 2004, In: Cancer. 100, 12, p. 2491-2499 9 p.

Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid

Murata, R. & Horsman, M. R., Jun 2004, In: International Journal of Hyperthermia. 20, 4, p. 393-404 12 p.

Targeting the tumor vasculature: a strategy to improve radiation therapy

Siemann, D. W. & Horsman, M. R., Apr 2004, In: Expert Review of Anticancer Therapy. 4, 2, p. 321-327 7 p.

Preclinical studies on how to deal with patient intolerance to nicotinamide and carbogen

Horsman, M. R. & Overgaard, J., Mar 2004, In: Radiotherapy & Oncology. 70, 3, p. 301-309 9 p.

Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma

Grönroos, T., Bentzen, L. N., Marjamäki, P., Murata, R., Horsman, M. R., Keiding, S., Eskola, O., Haaparanta, M., Minn, H. & Solin, O., 2004, In: European Journal of Nuclear Medicine and Molecular Imaging. 31, p. 513-520 8 p.

Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response

Horsman, M. R. & Murata, R., 15 Nov 2003, In: International Journal of Radiation Oncology, Biology, Physics. 57, 4, p. 1047-1055 9 p.

Intense inflammation in bladder carcinoma is associated with angiogenesis and indicates good prognosis

Offersen, B. V., Knap, M., Marcussen, N., Horsman, M. R., Hamilton-Dutoit, S. J. & Overgaard, J., 2 Dec 2002, In: British Journal of Cancer. 87, 12, p. 1422-1430 9 p.

Combination of vascular targeting agents with thermal and radiation therapy

Horsman, M. R. & Murata, R., 1 Dec 2002, In: International Journal of Radiation Oncology, Biology, Physics. 54, 5, p. 1518-1523 6 p.

Enhancement of radiation therapy by vascular targeting agents

Siemann, D. W. & Horsman, M. R., Nov 2002, In: Current Opinion in Investigational Drugs. 3, 11, p. 1660-1665 6 p.

Acute effects of vascular modifying agents in solid tumors assessed by non-invasive laser Doppler flowmetry (LDF) and near infrared spectroscopy (NIRS)

Kragh, M., Quistorff, B., Horsman, M. R. & Kristjansen, P. E. G., Jun 2002, In: NeoPlasia. 4, 3, p. 263-267 5 p.

Assessment of hypoxia in experimental mice tumours by [18F]fluoromisonidazole PET and pO2 electrode measurements. Influence of tumour volumes and carbogen breathing

Bentzen, L. N., Keiding, S., Horsman, M. R., Grönroos, T., Hansen, S. B. & Overgaard, J., 2002, In: Acta Oncologica. 41, 3, p. 304-312 9 p.

Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy

Murata, R., Overgaard, J. & Horsman, M. R., 15 Nov 2001, In: International Journal of Radiation Oncology, Biology, Physics. 51, 4, p. 1018-1024 7 p.

Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid

Murata, R., Siemann, D. W., Overgaard, J. & Horsman, M. R., Nov 2001, In: Radiation Research. 156, 5 pt 1, p. 503-509 7 p.

Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid

Murata, R., Overgaard, J. & Horsman, M. R., Nov 2001, In: International Journal of Hyperthermia. 17, 6, p. 508-519 12 p.

Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors

Murata, R., Siemann, D. W., Overgaard, J. & Horsman, M. R., Aug 2001, In: Radiotherapy & Oncology. 60, 2, p. 155-161 7 p.

Effect of changing tumor oxygenation on glycolytic metabolism in a murine C3H mammary carcinoma assessed by in vivo nuclear magnetic resonance spectroscopy

Nielsen, F. U., Daugård, P., Bentzen, L. N., Overgaard, J., Stødkilde-Jørgensen, H., Horsman, M. R. & Maxwell, R. J., 1 Jul 2001, In: Cancer Research. 61, 13, p. 5318-25 8 p.

Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues

Murata, R., Overgaard, J. & Horsman, M. R., Feb 2001, In: International Journal of Radiation Biology. 77, 2, p. 195-204 10 p.

A future for hyperthermia in cancer treatment?

Nielsen, O. S., Horsman, M. R. & Overgaard, J., 2001, In: European Journal of Cancer. 37, 13, p. 1587-9 3 p.

Effect of changing tumor oxygenation on glycolytic metabolism in a murine C3H mammary carcinoma assessed by in vivo Nuclear Magnetic Resonance spectroscopy

Nielsen, F. U., Christensen, P. D., Overgaard, J., Stødkilde-Jørgensen, H., Horsman, M. R. & Maxwell, R. J., 2001, In: Cancer Res.. 61, 13, p. 5318-5325 8 p.

Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation

Horsman, M. R., Murata, R. & Overgaard, J., 2001, In: Acta Oncologica. 40, 4, p. 497-503 7 p.

Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography--a study evaluating [18F]Fluoro-2-deoxy-D-glucose

Bentzen, L. N., Keiding, S., Horsman, M. R., Falborg, L., Hansen, S. B. & Overgaard, J., 2000, In: Acta Oncologica. 39, 5, p. 629-37 9 p.

Importance of overall treatment time for the response to radiotherapy in patients with squamous cell carcinoma of the head and neck

Overgaard, J., Alsner, J., Eriksen, J., Horsman, M. R. & Grau, C., 2000, In: Rays. 25, 3, p. 313-9 7 p.

Non-invasive tumour blood perfusion measurement by 2H magnetic resonance

Bentzen, L. N., Horsman, M. R., Daugaard, P. & Maxwell, R. J., 2000, In: NMR in Biomedicine. 13, 8, p. 429-37 9 p.

Localized in vivo 1H NMR spectroscopy of murine tumours: Effect of blood flow reduction

Nielsen, F. U., Topp, S-K., Horsman, M. R., Overgaard, J., Stødkilde-Jørgensen, H. & Maxwell, R. J., Jun 1999, In: NMR in Biomedicine. 12, 4, p. 175-83 9 p.

The ability of hypoxia to modify the gene expression of thymidylate synthase in tumour cells in vivo

Ehrnrooth, E., von der Maase, H., Sørensen, B. S., Poulsen, J. H. & Horsman, M. R., 1999, In: International Journal of Radiation Biology. 75, 7, p. 885-91 6 p.

Techniques to assess the oxygenation of human tumors. State of the art

Horsman, M. R., Nordsmark, M. & Overgaard, J., Dec 1998, In: Strahlentherapie und Onkologie. 174 , Suppl 4, p. 2-5 4 p.

The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors

Horsman, M. R., Ehrnrooth, E., Ladekarl, M. & Overgaard, J., 1 Nov 1998, In: International Journal of Radiation Oncology, Biology, Physics. 42, 4, p. 895-898 4 p.

The effect of shark cartilage extracts on the growth and metastatic spread of the SCCVII carcinoma

Horsman, M. R., Alsner, J. & Overgaard, J., 1998, In: Acta Oncologica. 37, 5, p. 441-5 5 p.

Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing

Horsman, M. R., Siemann, D. W., Chaplin, D. J. & Overgaard, J., Nov 1997, In: Radiotherapy & Oncology. 45, 2, p. 167-74 8 p.

Detection of hypoxic cells in a C3H mouse mammary carcinoma using the comet assay

Olive, P. L., Horsman, M. R., Grau, C. & Overgaard, J., 1 Jan 1997, In: British Journal of Cancer. 76, 6, p. 694-9 6 p.

Can mild hyperthermia improve tumour oxygenation?

Horsman, M. R. & Overgaard, J., 1997, In: International Journal of Hyperthermia. 13, 2, p. 141-7 7 p.

Effect of hydralazine in spontaneous tumours assessed by oxygen electrodes and 31P-magnetic resonance spectroscopy

Nordsmark, M., Maxwell, R. J., Wood, P. J., Stratford, I. J., Adams, G. E., Overgaard, J. & Horsman, M. R., Jul 1996, In: British Journal of Cancer. Supplement. 27, p. S232-S235 4 p.

Effect of nitro-L-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours

Horsman, M. R., Chaplin, D. J., Hill, S. A., Arnold, S., Collingridge, D., Radacic, M., Wood, P. J. & Overgaard, J., Jul 1996, In: British Journal of Cancer. Supplement. 27, p. S168-71 4 p.

Modification of Hypoxia-Induced Radioresistance in Tumors by the Use of Oxygen and Sensitizers

Overgaard, J. & Horsman, M. R., Jan 1996, In: Seminars in Radiation Oncology. 6, 1, p. 10-21 12 p.

A comparison of the physiological effects of RSU1069 and RB6145 in the SCCVII murine tumour

Wood, P. J., Horsman, M. R., Khalil, A. A., Steinberg, F., Streffer, C., Overgaard, J., Stratford, I. J. & Adams, G. E., 1996, In: Acta Oncologica. 35, 8, p. 989-94 6 p.

The in vivo interaction between flavone acetic acid and hyperthermia

Horsman, M. R., Sampson, L. E., Chaplin, D. J. & Overgaard, J., 1996, In: International Journal of Hyperthermia. 12, 6, p. 779-89 11 p.

Direct evidence that hydralazine can induce hypoxia in both transplanted and spontaneous murine tumours

Horsman, M. R., Nordsmark, M., Høyer, M. & Overgaard, J., Dec 1995, In: B J C. 72, 6, p. 1474-1478 5 p.

Relationship between tumour oxygenation, bioenergetic status and radiobiological hypoxia in an experimental model

Nordsmark, M., Grau, C., Horsman, M. R., Jörgensen, H. S. & Overgaard, J., 1 Jan 1995, In: Acta Oncologica. 34, 3, p. 329-34 6 p.

Reoxygenation in a C3H mouse mammary carcinoma. The importance of chronic rather than acute hypoxia

Horsman, M. R., Grau, C. & Overgaard, J., 1 Jan 1995, In: Acta Oncologica. 34, 3, p. 325-8 4 p.

The ability of nicotinamide to inhibit the growth of a C3H mouse mammary carcinoma

Horsman, M. R., Khalil, A. A., Chaplin, D. J. & Overgaard, J., 1995, In: Acta Oncologica. 34, 3, p. 443-6 4 p.

The importance of determining necrotic fraction when studying the effect of tumour volume on tissue oxygenation

Khalil, A. A., Horsman, M. R. & Overgaard, J., 1995, In: Acta Oncologica. 34, 3, p. 297-300 4 p.

Effect of carbon monoxide breathing on hypoxia and radiation response in the SCCVII tumor in vivo

Grau, C., Nordsmark, M., Khalil, A. A., Horsman, M. R. & Overgaard, J., 15 Jun 1994, In: International Journal of Radiation Oncology, Biology, Physics. 29, 3, p. 449-54 6 p.

Importance of nicotinamide dose on blood pressure changes in mice and humans

Horsman, M. R., Christensen, K. L. & Overgaard, J., 15 Jun 1994, In: International Journal of Radiation Oncology, Biology, Physics. 29, 3, p. 455-8 4 p.

Relationship between radiobiological hypoxia in tumors and electrode measurements of tumor oxygenation

Horsman, M. R., Khalil, A. A., Siemann, D. W., Grau, C., Hill, S. A., Lynch, E. M., Chaplin, D. J. & Overgaard, J., 15 Jun 1994, In: International Journal of Radiation Oncology, Biology, Physics. 29, 3, p. 439-42 4 p.

The relationship between carbon monoxide breathing, tumour oxygenation and local tumour control in the C3H mammary carcinoma in vivo

Grau, C., Khalil, A. A., Nordsmark, M., Horsman, M. R. & Overgaard, J., 1 Jan 1994, In: British Journal of Cancer. 69, 1, p. 50-7 8 p.

Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing

Horsman, M. R., Nordsmark, M., Khalil, A. A., Hill, S. A., Chaplin, D. J., Siemann, D. W. & Overgaard, J., 1994, In: Acta Oncologica. 33, 4, p. 371-6 6 p.

The combination of nicotinamide and carbogen breathing to improve tumour oxygenation prior to radiation treatment

Horsman, M. R., Siemann, D. W., Nordsmark, M., Khalil, A. A., Overgaard, J. & Chaplin, D. J., 1994, In: Advances in Experimental Medicine and Biology. 361, p. 635-642 8 p.

Use of tetrahydraindazolone dicarboxylic acid (HIDA) to improve the therapeutic effect in vivo of combined cisplatin, heat and radiation treatment

Overgaard, J., Radacic, M., Skaric, D., Skaric, V., Horsman, M. R., Lindegaard, J. C., Jercic, J. & Lindegaard, J. C., Dec 1993, In: International Journal of Hyperthermia. 9, 6, p. 821-30 10 p.

Relationship between radiobiological hypoxia and direct estimates of tumour oxygenation in a mouse tumour model

Horsman, M. R., Khalil, A. A., Nordsmark, M., Grau, C. & Overgaard, J., 1 Jul 1993, In: Radiotherapy & Oncology. 28, 1, p. 69-71 3 p.

Nicotinamide pharmacokinetics in humans and mice: A comparative assessment and the implications for radiotherapy

Horsman, M. R., Høyer, M., Honess, D. J., Dennis, I. F. & Overgaard, J., May 1993, In: Radiotherapy & Oncology. 27, 2, p. 131-139 9 p.

BW12C-induced changes in haemoglobin-oxygen affinity in mice and its influence on the radiation response of a C3H mouse mammary carcinoma

Horsman, M. R. & Overgaard, J., Sep 1992, In: Radiotherapy & Oncology. 25, 1, p. 43-8 6 p.

Cisplatin and hyperthermia treatment of a C3H mammary carcinoma in vivo. Importance of sequence, interval, drug dose, and temperature

Lindegaard, J. C., Radacic, M., Khalil, A. A., Horsman, M. R. & Overgaard, J., 1 Jan 1992, In: Acta Oncologica. 31, 3, p. 347-351 5 p.

Improving the radiation response in a C3H mouse mammary carcinoma by normobaric oxygen or carbogen breathing

Grau, C., Horsman, M. R. & Overgaard, J., 1 Jan 1992, In: International Journal of Radiation Oncology, Biology, Physics. 22, 3, p. 415-419 5 p.

Influence of carboxyhemoglobin level on tumor growth, blood flow, and radiation response in an experimental model

Grau, C., Horsman, M. R. & Overgaard, J., 1 Jan 1992, In: International Journal of Radiation Oncology, Biology, Physics. 22, 3, p. 421-424 4 p.

Biochemical and physiological changes induced by nicotinamide in a C3H mouse mammary carcinoma and CDF1 mice

Horsman, M. R., Kristjansen, P. E. G., Mizuno, M., Christensen, K. L., Chaplin, D. J., Quistorff, B. & Overgaard, J., 1992, In: International Journal of Radiation Oncology, Biology, Physics. 22, 3, p. 451-454 4 p.

Overcoming tumour radiation resistance resulting from acute hypoxia

Horsman, M. R. & Overgaard, J., 1992, In: European journal of cancer (Oxford, England : 1990). 28A, 12, p. 2084-5 2 p.

Overcoming tumour radiation resistance resulting from acute hypoxia

Horsman, M. R. & Overgaard, J., 1992, In: European journal of cancer (Oxford, England : 1990). 28A, 4-5, p. 717-718 2 p.

Relationship between the hydralazine-induced changes in murine tumor blood supply and mouse blood pressure

Horsman, M. R., Christensen, K. L. & Overgaard, J., 1992, In: International Journal of Radiation Oncology, Biology, Physics. 22, 3, p. 455-8 4 p.

The potential of using hyperthermia to eliminate radioresistant hypoxic cells

Overgaard, J., Grau, C., Lindegaard, J. C. & Horsman, M. R., 1 Jan 1991, In: Radiotherapy & Oncology. 20 , Suppl 1, p. 113-116 4 p.

Hydralazine-induced changes in tissue perfusion and radiation response in a C3H mammary carcinoma and mouse normal tissues

Fisker, R. V., Horsman, M. R. & Overgaard, J., 1991, In: Acta Oncologica. 30, 5, p. 641-647 7 p.

The effect of combining flavone acetic acid and hyperthermia on the growth of a C3H mammary carcinoma in vivo

Horsman, M. R., Chaplin, D. J. & Overgaard, J., 1991, In: International Journal of Radiation Biology. 60, 1-2, p. 385-388 4 p.

The use of blood flow modifiers to improve the treatment response of solid tumors

Horsman, M. R., Chaplin, D. J. & Overgaard, J., 1991, In: Radiotherapy & Oncology. 20, Suppl 1, p. 47-52 6 p.

Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells

Horsman, M. R., Chaplin, D. J. & Overgaard, J., 1 Dec 1990, In: Cancer Research. 50, 23, p. 7430-7436 7 p.

The potentiation of radiation damage by nicotinamide in the SCCVII tumour in vivo

Horsman, M. R., Wood, P. J., Chaplin, D. J., Brown, J. & Overgaard, J., May 1990, In: Radiotherapy & Oncology. 18, 1, p. 49-57 9 p.

Invasive blood pressure measurements in restrained but non-anaesthetized mice

Christensen, K. L., Horsman, M. R. & Overgaard, J., Feb 1990, In: In Vivo. 4, 1, p. 13-16 4 p.

Radiosensitization by nicotinamide in tumors and normal tissues: the importance of tissue oxygenation status

Horsman, M. R., Hansen, P. V. & Overgaard, J., May 1989, In: International Journal of Radiation Oncology, Biology, Physics. 16, 5, p. 1273-1276 4 p.

Mechanism for the reduction of tumour hypoxia by nicotinamide and the clinical relevance for radiotherapy

Horsman, M. R., Overgaard, J., Christensen, K. L., Trotter, M. J. & Chaplin, D. J., 1989, In: Biomedica Biochimica Acta. 48, 2-3, p. S251-4

Mechanism of action of the selective tumor radiosensitizer nicotinamide

Horsman, M. R., Brown, J. M., Hirst, V. K., Lemmon, M. J., Wood, P. J., Dunphy, E. P. & Overgaard, J., Sep 1988, In: International Journal of Radiation Oncology, Biology, Physics. 15, 3, p. 685-690 6 p.

The interaction between RSU-1069, hydralazine and hyperthermia in a C3H mammary carcinoma as assessed by tumour growth delay

Horsman, M. R., Overgaard, J. & Chaplin, D. J., 1988, In: Acta oncologica (Stockholm, Sweden). 27, 6b, p. 861-2 2 p.

Cell-wall studies of Pseudomonas aeruginosa and its carbenicillin-induced L-form [proceedings]

White, C. J. B., Rowe, P. S., Horsman, M. R. & Spicer, A. B., 1977, In: Biochemical Society. Transactions. 5, 5, p. 1496-1498 3 p.